Gabrielle Sulzberger net worth and biography

Gabrielle Sulzberger Biography and Net Worth

Director of Eli Lilly and Company

Gabrielle Sulzberger serves as a Senior Managing Director at Centerbridge Partners, where she previously served as a Senior Advisor from 2021 to 2024. She also serves as a Senior Advisor at Teneo, a global CEO advisory firm, where she previously served as Chair of Global ESG Advisory from 2021 to May 2024. Sulzberger was elected to the Eli Lilly and Company board of directors in 2021.

Sulzberger previously served as a strategic advisor to Two Sigma Impact, a New York based private equity fund. She was also a general partner of Rustic Canyon/Fontis Partners, a private equity fund based in Pasadena, California, focused on socially responsible investing. Sulzberger has previously served as principal of several private equity funds over her 30-year career in financial services, as well as chief financial officer of several public and private companies.

Sulzberger holds a Bachelor of Arts from the Woodrow Wilson School of Princeton University, a Master of Business Administration from Harvard Business School, and a Juris Doctor from Harvard Law School.

Sulzberger is a member of the boards of directors of Mastercard and several other private companies. Among her previous board positions, Sulzberger served as chairman of the board of Whole Foods.

Sulzberger is also trustee of the Ford Foundation and is chair of its governance committee. She also serves on the boards of The Metropolitan Museum of Art and the Sesame Street Workshop. She is a Henry Crown Fellow of the Aspen Institute.

What is Gabrielle Sulzberger's net worth?: The estimated net worth of Gabrielle Sulzberger is at least $2.73 million as of August 12th, 2025. Ms. Sulzberger owns 2,703 shares of Eli Lilly and Company stock worth more than $2,734,733 as of December 4th. This net worth evaluation does not reflect any other assets that Ms. Sulzberger may own. Learn More about Gabrielle Sulzberger's net worth.
How do I contact Gabrielle Sulzberger?: The corporate mailing address for Ms. Sulzberger and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Gabrielle Sulzberger's contact information.
Has Gabrielle Sulzberger been buying or selling shares of Eli Lilly and Company?: Gabrielle Sulzberger has not been actively trading shares of Eli Lilly and Company within the last three months. Most recently, on Tuesday, August 12th, Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director now directly owns 2,703 shares of the company's stock, valued at $1,733,109.54. Learn More on Gabrielle Sulzberger's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), J. Fyrwald (Director), Michael Harrington (VP), Jamere Jackson (Director), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Gabrielle Sulzberger (Director), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, Eli Lilly and Company insiders bought shares 5 times. They purchased a total of 4,514 shares worth more than $2,894,841.15. In the last year, insiders at the sold shares 1 times. They sold a total of 1,000 shares worth more than $818,240.00. The most recent insider tranaction occured on August, 12th when CEO David A Ricks bought 1,632 shares worth more than $1,052,264.64. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 8/12/2025.

Gabrielle Sulzberger Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/12/2025	Buy	117	$641.18	$75,018.06	2,703

Gabrielle Sulzberger Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $1,011.74

$1,007.18

$1,032.63

50 Day Range

MA: $913.15

$724.73

$1,109.09

2 Week Range

Now: $1,011.74

$623.78

$1,111.99

Volume

3,853,037 shs

Average Volume

3,914,035 shs

Market Capitalization

$956.48 billion

P/E Ratio

49.50

Dividend Yield

0.58%

Beta

0.37